Details of the Drug Combinations

General Information of This Drug (ID: DMOJV2N)

Drug Name

TAS-102 DMOJV2N

Synonyms

Tipiracil / Trifluridine; Viroptic mixture with 5-CIMU; TAS 102; EX-A1755; Tipiracil hydrochloride / Trifluridine; Tipiracil hydrochloride mixture with Trifluridine; 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione compound with 5-chloro-6-((2-iminopyrrolidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione (1:1) hydrochloride; Thymidine, alpha,alpha,alpha-trifluoro-, mixt. with 5-chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione monohydro

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Trifluridine + TAS-102	DCQKB2S	Trifluridine	Metastatic Colorectal Cancer	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01955837) Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04854434) A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations